All In MedTech

Device Trial Radar · NCT04295707

Monthly Replacement Orthokeratology for Myopia Control in Existing Lens Wearers

Accrued Effect of Orthokeratology for Myopia Control in Children and the Effectiveness of Myopia Control Using an Innovative Orthokeratology Modality. Experiment 1. Effect in Existing Ortho-k Wearers

Last checked: Nov 20, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Mar 11, 2020

Primary completion

Jun 2023

Study completion Aug 2023

Sponsor

Lead sponsor
The Hong Kong Polytechnic UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Menicon Co., Ltd.
First posted
Mar 4, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 8 years, up to 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The two-year prospective study aims at investigating the benefits of frequent replacement (monthly) orthokeratology lenses in myopia control in terms of effectiveness in control and prevention of ocular complications. The secondary objective will be investigating the use of weekly protein removal system in monthly replacement modality orthokeratology lenses on surface deposit.

Conditions

  • Myopic Progression

Interventions

  • orthokeratologyDevice

    Nightly wear of orthokeratology lenses to correct vision in the daytime

  • Menicon Progent A+BDevice

    Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Axial elongation in 2 yearsTime frame: 2 years
  2. Back Surface Lens DepositsTime frame: Every month up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • School of Optometry, The Hong Kong Polytechnic University

    Kowloon, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.